Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBT (2016 - 2025)

Corcept Therapeutics' EBT history spans 10 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, EBT fell 68.99% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $66.5 million, down 58.84%, while the annual FY2025 figure was $66.5 million, 58.84% down from the prior year.
  • EBT for Q4 2025 was $9.9 million at Corcept Therapeutics, down from $15.2 million in the prior quarter.
  • Across five years, EBT topped out at $52.9 million in Q3 2024 and bottomed at $9.6 million in Q1 2025.
  • The 5-year median for EBT is $32.1 million (2021), against an average of $29.7 million.
  • The largest annual shift saw EBT surged 89.83% in 2024 before it crashed 72.51% in 2025.
  • A 5-year view of EBT shows it stood at $36.7 million in 2021, then plummeted by 33.92% to $24.3 million in 2022, then skyrocketed by 51.63% to $36.8 million in 2023, then fell by 13.17% to $32.0 million in 2024, then plummeted by 68.99% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's EBT are $9.9 million (Q4 2025), $15.2 million (Q3 2025), and $31.7 million (Q2 2025).